Repositorio Dspace

Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity

Mostrar el registro sencillo del ítem

dc.contributor.author Melgosa-Ramos, Francisco-Javier
dc.contributor.author Mercader-García, Pedro
dc.contributor.author Santos-Alarcon, Sergio
dc.contributor.author Domínguez-Liron, Nalia
dc.contributor.author Bernabeu, Andrea
dc.contributor.author Rodríguez-Serna, Mercedes
dc.contributor.author Fernández-Crehuet, Pablo
dc.contributor.author Silvestre, Juan-Francisco
dc.date.accessioned 2026-08-03T10:30:45Z
dc.date.available 2026-08-03T10:30:45Z
dc.date.issued 2026-07
dc.identifier.issn 2193-8210
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/27180
dc.description.abstract INTRODUCTION: Patients with moderate-to-severe atopic dermatitis (AD) and significant comorbidities are frequently excluded from randomized clinical trials, limiting the applicability of evidence to these clinically complex patients. We evaluated the effectiveness and safety of tralokinumab in this setting. METHODS: Multicenter retrospective study including adults with moderate-to-severe AD treated with tralokinumab (300 mg every 2 weeks) in Spanish tertiary hospitals (June 2022-December 2025). Special populations included patients with malignancies, advanced cardiovascular or renal disease, chronic infections, or neurologic disorders. Outcomes included Eczema Area and Severity Index (EASI), pruritus NRS, safety events, and treatment optimization. Analyses were descriptive. RESULTS: Twenty-one patients (aged 27-90 years) with high multimorbidity burden were included. Comorbidities comprised malignancies (n = 9), advanced heart disease (n = 7), neurologic disorders (n = 4), chronic kidney disease (n = 2), latent tuberculosis (n = 2), and HIV (n = 2). Mean EASI decreased from 19.3 to 3.45 (~ 82% reduction) and pruritus Numeric Rating Scale (NRS) from 7 to 2 (~ 71% reduction) after a mean follow-up of 24.6 months. Approximately 70% achieved EASI ? 3 and 50% EASI 0-1. Median follow-up was 24.6 months. Dose interval extension was feasible in 33.3% of patients. No tumor progression, infection reactivation, major cardiovascular events, or severe adverse events were observed. CONCLUSIONS: Tralokinumab showed sustained effectiveness and a favorable safety profile in clinically complex patients with AD. These real-world findings support IL-13 blockade as a valuable therapeutic option for multimorbid populations that are underrepresented in clinical trials.
dc.language.iso eng
dc.publisher ADIS INT LTD
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional 
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.title Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42168711
dc.relation.publisherversion https://link.springer.com/10.1007/s13555-026-01795-x
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1007/s13555-026-01795-x
dc.journal.title DERMATOLOGY AND THERAPY
dc.identifier.essn 2190-9172


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional  Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional 

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta